Disease relevance of Deja Vu

• Type III secretion in Chlamydia: a case of déjà vu [1]?
• The authors studied the functional anatomy of the déjà vu (DV) experience in nonlesional temporal lobe epilepsy (TLE), using interictal fluorine-18 fluorodeoxyglucose PET in 14 patients with and 17 patients without DV [2].

Psychiatry related information on Deja Vu

• The combination of déjà vu, a cephalic sensation, a warm sensation, a gustatory hallucination, and an indescribable strange sensation discriminated best between the 25 patients with a normal and the 25 patients with an abnormal AT2 [3].
• Age differences are examined in reports of deja vu, ESP, clairvoyance, spiritualism, and numinous experience [4].

High impact information on Deja Vu

• Déjà vu guides the way to new antimicrobial steroid [5].
• Déjà Vu all over again: chimp-language wars [6].
• Short-term corticosteroid therapy in combination with lamivudine: A case of déjà vu [7]?
• Anatomical origin of déjà vu and vivid 'memories' in human temporal lobe epilepsy [8].
• Déjà vu: angiotensin and stress [9].

Chemical compound and disease context of Deja Vu

• Vitamin C pharmacokinetics: it's déjà vu all over again [10].
• Empiric lidocaine: Déjà vu (all over again?) [11].
• Sevoflurane and seizures: déjà vu [12].
• Acetaldehyde: déjà vu du jour [13].
• Operative dentistry: déjà vu, redux [14].

Gene context of Deja Vu

• Transplant IgA nephropathy: déjà vu again [15]?
• Déjà vu, a warm sensation, an indescribable strange sensation, a cephalic sensation, and fear were associated with an abnormal AT2 [3].
• Déjà vu all over again: FMRP binds U-rich target mRNAs [16].
• Growth hormone in youth and old age (the old and new déja vu) [17].
• Beta2 déjà vu [18].

References